{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:31:51Z","timestamp":1786120311357,"version":"build-2736575974"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1097\/mop.0b013e32834cba24","type":"journal-article","created":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T03:43:50Z","timestamp":1320119030000},"page":"640-646","source":"Crossref","is-referenced-by-count":24,"title":["Update on the pathogenesis and treatment of systemic idiopathic arthritis"],"prefix":"10.1097","volume":"23","author":[{"given":"Keith A.","family":"Sikora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexei A.","family":"Grom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210206","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0950-3579(98)80018-6","article-title":"Systemic onset juvenile rheumatoid arthritis.","volume":"12","author":"Schneider","year":"1998","journal-title":"Baillieres Clin Rheumatol"},{"key":"R2-13-20210206","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S0022-3476(83)80704-5","article-title":"Consumption coagulopathy associated with systemic juvenile rheumatoid arthritis.","volume":"103","author":"Silverman","year":"1983","journal-title":"J Pediatr"},{"key":"R3-13-20210206","first-page":"451","article-title":"Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases.","volume":"11","author":"Stephan","year":"1993","journal-title":"Clin Exp Rheumatol"},{"key":"R4-13-20210206","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/art.22416","article-title":"The diagnostic significance of soluble CD163 and soluble interleukin-2 alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis.","volume":"56","author":"Bleesing","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R5-13-20210206","first-page":"1133","article-title":"Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis.","volume":"34","author":"Behrens","year":"2007","journal-title":"J Rheumatol"},{"key":"R6-13-20210206","first-page":"1350","article-title":"Does systemic-onset juvenile idiopathic arthritis belong under juvenile idiopathic arthritis Rheumatology (Oxford","volume":"44","author":"Ramanan","year":"2005","journal-title":")"},{"key":"R7-13-20210206","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/ncprheum0084","article-title":"Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome.","volume":"2","author":"Woo","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"R8-13-20210206","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/nature02761","article-title":"Inferences, questions and possibilities in Toll-like receptor signaling.","volume":"430","author":"Beutler","year":"2004","journal-title":"Nature"},{"key":"R9-13-20210206","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00002281-200301000-00011","article-title":"The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations.","volume":"15","author":"Hull","year":"2003","journal-title":"Curr Opin Rheumatol"},{"key":"R10-13-20210206","first-page":"70","article-title":"Juvenile rheumatoid arthritis and HLA: report of the Park City III workshop.","volume":"33","author":"Nepom","year":"1992","journal-title":"J Rheumatol Suppl"},{"key":"R11-13-20210206","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1172\/JCI2629","article-title":"The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis.","volume":"102","author":"Fishman","year":"1998","journal-title":"J Clin Invest"},{"key":"R12-13-20210206","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1002\/art.11300","article-title":"The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multicenter study using simplex and multiplex juvenile idiopathic arthritis families.","volume":"48","author":"Ogilvie","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R13-13-20210206","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1002\/1529-0131(200108)44:8<1782::AID-ART314>3.0.CO;2-#","article-title":"A novel 5-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis.","volume":"44","author":"Donn","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R14-13-20210206","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/art.10882","article-title":"Functional and prognostic relevance of the -173 polymorphism of the macrophage inhibitory factor gene in systemic-onset juvenile idiopathic arthritis.","volume":"48","author":"De Benedetti","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R15-13-20210206","doi-asserted-by":"crossref","first-page":"R148","DOI":"10.1186\/ar2041","article-title":"Novel IL10 gene family associations with systemic idiopathic arthritis.","volume":"8","author":"Fife","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"R16-13-20210206","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1002\/1529-0131(199912)42:12<2577::AID-ANR10>3.0.CO;2-O","article-title":"Identification of a genetic risk factor for systemic juvenile rheumatoid arthritis in the 5-flanking region of the TNFalpha gene and HLA genes.","volume":"42","author":"Date","year":"1999","journal-title":"Arthritis Rheum"},{"key":"R17-13-20210206","first-page":"912","article-title":"IL-10 promoter polymorphisms are associated with systemic onset juvenile idiopathic arthritis (SoJIA).","volume":"28","author":"Moller","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"R18-13-20210206","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/gene.2008.24","article-title":"Comprehensive association study of genetic variants in the IL-1 gene family in systemic juvenile idiopathic arthritis.","volume":"9","author":"Stock","year":"2008","journal-title":"Genes Immun"},{"key":"R19-13-20210206","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/art.22444","article-title":"British Society of Paediatric and Adolescent RheumatologyPositive association of SLC26A2 gene polymorphisms with susceptibility to systemic-onset juvenile idiopathic arthritis.","volume":"56","author":"Lamb","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R20-13-20210206","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20050473","article-title":"Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade.","volume":"201","author":"Pascual","year":"2005","journal-title":"J Exp Med"},{"key":"R21-13-20210206","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1002\/art.22981","article-title":"Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome.","volume":"56","author":"Fall","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R22-13-20210206","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1002\/art.22644","article-title":"Specific gene expression profiles in systemic juvenile idiopathic arthritis.","volume":"56","author":"Ogilvie","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R23-13-20210206","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1002\/art.24601","article-title":"Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis.","volume":"60","author":"Barnes","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R24-13-20210206","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/378088a0","article-title":"Cloning of a new cytokine that induces IFN-gamma production by T cells.","volume":"378","author":"Okamura","year":"1995","journal-title":"Nature"},{"key":"R25-13-20210206","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/rheumatology\/keq133","article-title":"Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis.","volume":"49","author":"Shimizu","year":"2010","journal-title":"Rheumatology"},{"key":"R26-13-20210206","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1084\/jem.160.1.310","article-title":"Immune response-associated production of neopterin.","volume":"160","author":"Huber","year":"1984","journal-title":"J Exp Med"},{"key":"R27-13-20210206","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/rheumatology\/37.11.1240","article-title":"The use of intravenous pulsed methylprednisolone in the treatment of systemic-onset juvenile chronic arthritis.","volume":"37","author":"Adebajo","year":"1998","journal-title":"Br J Rheumatol"},{"key":"R28-13-20210206","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1136\/ard.2003.014886","article-title":"The German etanercept registry for treatment of juvenile idiopathic arthritis (JIA).","volume":"63","author":"Horneff","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"R29-13-20210206","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/art.10885","article-title":"Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to onset type.","volume":"48","author":"Quartier","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R30-13-20210206","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1002\/1529-0131(200008)43:8<1849::AID-ANR22>3.0.CO;2-F","article-title":"Randomised placebo-controlled crossover trial with low dose oral methotrexate in children with extended oligoarticular or systemic arthritis.","volume":"43","author":"Woo","year":"2000","journal-title":"Arthritis Rheum"},{"key":"R31-13-20210206","first-page":"935","article-title":"Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis.","volume":"32","author":"Kimura","year":"2005","journal-title":"J Rheumatol"},{"key":"R32-13-20210206","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/rheumatology\/keq308","article-title":"Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients.","volume":"50","author":"Southwood","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"R33-13-20210206","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2007.076034","article-title":"Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.","volume":"67","author":"Lequerre","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R34-13-20210206","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS).","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R35-13-20210206","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/art.23437","article-title":"The pattern of response to antiinterleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis.","volume":"58","author":"Gattorno","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R36-13-20210206","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1358\/dot.2009.45.6.1378935","article-title":"Rilonacept in the treatment of chronic inflammatory disorders.","volume":"45","author":"McDermott","year":"2009","journal-title":"Drugs Today"},{"key":"R37-13-20210206","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1002\/art.23620","article-title":"A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome.","volume":"58","author":"Goldbach-Mansky","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R38-13-20210206","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1002\/art.23687","article-title":"Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.","volume":"58","author":"Hoffman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R39-13-20210206","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1586\/eci.10.66","article-title":"Canakinumab: a human anti-IL-1 monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes.","volume":"6","author":"Church","year":"2010","journal-title":"Expert Rev Clin Immunol"},{"key":"R40-13-20210206","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/art.1780340912","article-title":"Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis.","volume":"34","author":"De Benedetti","year":"1991","journal-title":"Arthritis Rheum"},{"key":"R41-13-20210206","first-page":"1403","article-title":"Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis.","volume":"24","author":"De Benedetti","year":"1997","journal-title":"J Rheumatol"},{"key":"R42-13-20210206","doi-asserted-by":"crossref","first-page":"R1281","DOI":"10.1186\/ar1826","article-title":"Open label phase II trial of single dose, ascending dose of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement.","volume":"7","author":"Woo","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"R43-13-20210206","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/art.20944","article-title":"Therapeutic efficacy of humanized recombinant antiinterleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis.","volume":"52","author":"Yokota","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R44-13-20210206","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"R46-13-20210206","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.30128","article-title":"Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series.","volume":"63","author":"Nigrovic","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R47-13-20210206","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20460","article-title":"American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features.","volume":"63","author":"Beukelman","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MOP.0b013e32834cba24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:29:59Z","timestamp":1786048199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00008480-201112000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0b013e32834cba24","relation":{},"ISSN":["1040-8703"],"issn-type":[{"value":"1040-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}